Moderna Inc (MRNA)vsRoyalty Pharma Plc (RPRX)
MRNA
Moderna Inc
$225.00
+14.21%
HEALTHCARE · Cap: $75.86B
RPRX
Royalty Pharma Plc
$57.78
+1.49%
HEALTHCARE · Cap: $33.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 14% more annual revenue ($2.54B vs $2.23B). RPRX leads profitability with a 32.0% profit margin vs -141.4%. RPRX earns a higher WallStSmart Score of 57/100 (C).
MRNA
Avoid21
out of 100
Grade: F
RPRX
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$134.59
Current Price
$225.00
$90.41 discount
Margin of Safety
-53.0%
Fair Value
$37.22
Current Price
$57.78
$20.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Areas to Watch
Trading at 13.3x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Weak financial health signals
Earnings declined 46.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Debt/Equity, Piotroski F-Score.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while RPRX is a growth play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
RPRX is growing revenue faster at 16.5% — sustainability is the question.
RPRX generates stronger free cash flow (686M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (57/100 vs 21/100), backed by strong 32.0% margins and 16.5% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?